[1] Wong F, O＇Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology, 2013, 145: 1280-1288.
[2] Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis Hepatology, 2013, 57: 753-762.
[3] Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology, 2008, 48: 2064-2077.
[4] Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol, 2006, 4: 1385-1394.
[5] Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet, 2003, 362: 1819-1827.
[6] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015, 62: 968-974.
[7] Waikar SS, Betensky RA, Emerson SC, et al. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol, 2012, 23: 13-21.
[8] Wheeler DS, Devarajan P, Ma Q, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med, 2008, 36: 1297-1303.
[9] Fagundes C, Pepin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol, 2012, 57: 267-273.
[10] Barreto R, Elia C, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol, 2014, 61: 35-42.
[11] Prozialeck WC, Vaidya VS, Liu J, et al. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int, 2007, 72: 985-993.
[12] Ichimura T, Brooks CR, Bonventre JV. Kim-1/Tim-1 and immune cells: shifting sands. Kidney Int, 2012, 81: 809-811.
[13] Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol, 2010, 28: 455-462.
[14] Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol, 2010, 28: 478-485.
[15] Gonzalez F, Vincent F. Biomarkers for acute kidney injury in critically ill patients. Minerva Anestesiol, 2012, 78: 1394-1403.
[16] Wu H, Craft ML, Wang P, et al. IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol, 2008, 19: 2331-2341.
[17] Lin X, Yuan J, Zhao Y, et al. Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis. J Nephrol, 2015, 28: 7-16.
[18] Andreucci M, Faga T, Riccio E, et al. The potential use of biomarkers in predicting contrast-induced acute kidney injury. Int J Nephrol Renovasc Dis, 2016, 9: 205-221.
[19] Belcher JM, Sanyal AJ, Garcia-Tsao G, et al. Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol, 2014: 708585.
[20] Susantitaphong P, Siribamrungwong M, Doi K, et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am J Kidney Dis, 2013, 61: 430-439.
[21] Parr SK, Clark AJ, Bian A, et al. Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury. Kidney Int, 2015, 87: 640-648.
[22] Cho E, Yang HN, Jo SK, et al. The role of urinary liver-type fatty acid-binding protein in critically ill patients. J Korean Med Sci, 2013, 28: 100-105.
[23] Heung M, Ortega LM, Chawla LS, et al. Common chronic conditions do not affect performance of cell cycle arrest biomarkers for risk stratification of acute kidney injury. Nephrol Dial Transplant, 2016, 31: 1633-1640.
[24] Humphreys BD, Cantaluppi V, Portilla D, et al. Targeting endogenous repair pathways after AKI. J Am Soc Nephrol, 2016, 27: 990-998.
[25] Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care, 2013, 17: R25.
[26] Aydogdu M, Boyaci N, Yuksel S, et al. A promising marker in early diagnosis of septic acute kidney injury of critically ill patients: urine insulin like growth factor binding protein-7. Scand J Clin Lab Invest, 2016, 76: 402-410.
[27] Liu KD, Vijayan A, Rosner MH, et al. Clinical adjudication in acute kidney injury studies: findings from the pivotal TIMP-2*IGFBP7 biomarker study. Nephrol Dial Transplant, 2016, 31: 1641-1646.
[28] Vijayan A, Faubel S, Askenazi DJ, et al. Clinical use of the urine biomarker [TIMP-2]x[IGFBP7] for acute kidney injury risk assessment. Am J Kidney Dis, 2016, 68: 19-28.
[29] Dusse F, Edayadiyil-Dudasova M, Thielmann M, et al. Early prediction of acute kidney injury after transapical and transaortic aortic valve implantation with urinary G1 cell cycle arrest biomarkers. BMC Anesthesiol, 2016, 16: 76.
[30] Gandhi PU, Chow SL, Rector TS, et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. J Card Fail, 2017, 23: 20-28.
[31] Gunnerson KJ, Shaw AD, Chawla LS, et al. TIMP2*IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical patients. J Trauma Acute Care Surg, 2016, 80: 243-249.
[32] Meersch M, Schmidt C, Van Aken H, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury after pediatric cardiac surgery. PLoS One, 2014, 9: e110865. |
